← Back to screener

Maze Therapeutics, Inc. MAZE

Rank #1885 · Nasdaq · $1.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
39.7
P/E
33.4
P/B
-5.60
ROE
-16.8%
Op. Margin
34.4%
Debt Ratio
-14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 33.4x, P/B -5.60x. Ranks in the top 72% of the universe.

Profitability ★★★☆☆
Average

ROE -16.8%. Ranks in the top 44% of the universe.

Safety ★★★★★
Excellent

Debt ratio -14%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2025$0.2B$0.1B$0.1B$-0.3B34.4-14

← See the full screener